Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

These drugs reduce the cholesterol your body makes and help clear out LDL in your blood vessels where they can leave ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Amgen (NASDAQ:AMGN – Get Free Report) had its target price dropped by equities research analysts at Wells Fargo & Company ...